PD049 - HUMORAL IMMUNE RESPONSE IN SARS-COV-2 VACCINATED HIV-VERTICALLY TRANSMITTED PATIENTS (ID 1498)
Abstract
Backgrounds:
Certain vaccines prompt suboptimal responses in PLWH. The effect of SARS-CoV-2 vaccines and its long-lived immune response in vertically transmitted HIV young individuals has not been fully investigated yet.
Methods
In this study, we assessed SARS-CoV-2-specific neutralizing antibody titer (NTA) against both the European (EU, lineage B.1) and the Delta (D, B.1.617.2) strains in 22 BNT162b2 mRNA-vaccinated ART-treated patients reporting vertically-transmitted HIV infection and followed at the Pediatric Infective Disease Unit of Luigi Sacco Hospital, Milan, Italy. Analyses were performed over 7 months from the first vaccine dose (T0: one day before vaccination; T1: 25 days after II dose; T2: 6 months after II dose). Results at 6 months were compared with those obtained in 20 BNT162b2 mRNA-vaccinated HIV-negative age-matched volunteers.
Results:
In PLWH the percentage of waning of NTA from T1 to T2 was similar when comparing EU and the D strains (87,5% and 82%, respectively), although the Delta strains displayed a moderate immune escape, as demonstrated by the lower neutralization titer (EU T1= 456; D T1= 144). HIV patient with a history of SARS-CoV-2 infection reported higher levels of NTA, both at T1 and T2, and a lower titer dropping compared to individuals without experience of natural SARS-CoV-2 infection (42,7% vs 87,5% respectively). Comparing the results at 6 months with those obtained in HIV-negative age-matched volunteers, no significant differences emerged between the two groups.
Conclusions/Learning Points:
BNT162b2 mRNA vaccine is highly immunogenic, supporting vaccination for ART-responder HIV-infected subjects. NTA is considered a correlate of protection from SARS-CoV-2 and the effects of waning immunity predicts a loss of protection after vaccination. A booster vaccination should enable higher neutralization to SARS-CoV-2 than is achieved with primary vaccination also in HIV-vertically transmitted young individuals.
/thumbnails/0.jpg)
